VLV (virus like vaccine): ERV (endogenous retrovirus)。ERVはヒトの内在性ウイルスでゲノムの8%を占めています。通常細胞では不活性状態ですが、いくつかのガンで検出されます。
目的タンパク質
免疫の賦活化対象をERVと目的タンパク質の両方に向ける戦略
Congratulations to partner InProTher on their published article discussing the potential of #adenovirus to target endogenous retroviruses (ERVs) and help fight diseases including #cancer. Our licensing agreement with InProTher includes coverage of SIRION’s adenovirus technologies to cancer #vaccines encoding ERV-derived antigens for active #immunotherapy. https://bit.ly/2Zn4d72 #viralvectors
Figure 2
Illustration of the immune responses elicited by adenovirus based virus-like-vaccine (VLV) vaccination encoding endogenous retroviral (ERV) genes.
(1)
Vaccination with the adenoviral vector (Ad) encoding GAG and ENV genes, ideally harbouring mutations in the immunosuppressive domain (ISD) of ENV, is injected.
(2)
At the site of injection Ad directly infects professional antigen presenting cells (APCs) and releases the transgene into the recipient cell nucleus. (3)
In the nucleus, the viral DNA codes for both viral and transgene proteins. Following their production, the fate of these proteins can be:
(4)
release of virus-like-particles (VLP)s to stimulate B-cells in an antigen structure dependent way;
(5)
uptake by APCs for endosomal degradation, presentation on major histocompatibility complex class II molecules (MHC-II), or
(6)
degradation in the proteasome (directly or after uptake) for presentation on major histocompatibility complex class I molecules (MHC-I)
(7)
stimulation of CD4+ T-cells and subsequent B-cell stimulation, and stimulation of CD8+ T-cells.
/ Our new packaging and producer cell lines for #scalable #lentiviral manufacture of new #celltherapies. (細胞治療としてLentiviralのスケーラブルなのPCL)
/ An innovative new technology for scalable #AAV production that we hope will completely change the way #genetherapies are manufactured. (革新的なAAVのスケーラプルな製造技術)
/ A mammalian display #antibodydiscovery platform that self-labels when antibodies bind to the target membrane protein (哺乳動物細胞による膜タンパク質に結合する抗体があれば自己標識する探索プラットフォーム)
/ How we’ve adapted our #CRISPR engineering workflow to reliably edit #iPSCs (多機能幹細胞を編集する最適化されたCRISPRエンジニアリング・ワークフロー)
/ How our proprietary in house laboratory information management system is keeping us on track, and keeping our partners informed, in real time. (社内の実験情報マネジメント・システムは、情報をリアルタイムに提供する)
Achieving High-Yield Production of Functional AAV5 Gene Delivery Vectors via Fedbatch in an Insect Cell-One Baculovirus Sytstem (2019) – Methods & Clinical Development – より
当サイトでは、利便性向上や閲覧追跡にGoogle・他提携サービスによりCookieを使用しています。サイトの閲覧を続けた場合Cookieの使用に同意したことになります。.理解しました拒否Read More
プライバシーポリシー
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.